Clinical Trial Update: A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated the long-term safety of Octreotide Subcutaneous Depot in patients with acromegaly. The study sponsored by Camurus AB has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Octreotide Subcutaneous Depot (octreotide)

Snippet

Sponsor: Camurus AB | Conditions: Acromegaly | Phase 3 | Status: COMPLETED